Document Detail


Ocular and orbital blood flow velocity in patients with peripheral vascular disease and diabetes treated with intravenous prostaglandin E1.
MedLine Citation:
PMID:  11777176     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to evaluate the effect of intravenous prostaglandin E1 (PGE1) on the flow velocity of the ophthalmic artery and the central retinal artery in patients with peripheral vascular disease manifested by intermittent claudication. The flow velocity of these vessels is frequently decreased in vascular patients. Since these patients were already being treated with PGE1 for their intermittent claudication, the authors wanted to evaluate the effect on the flow velocity of the ocular vessels as well. A randomized 21-week study of two groups of vascular patients was performed. The first group had intermittent claudication. The second group had intermittent claudication and were also diabetics. Both groups were treated with intravenous PGE1 for their intermittent claudication. Using the color Doppler, the flow velocities of the ophthalmic artery and central retinal artery were measured before and after the intravenous treatment. Before treatment, the flow velocity of the ophthalmic artery and the central retinal artery was decreased when compared to that in the normals. After treatment, there was a significant increase in the systolic and diastolic phases of the flow velocity in both arteries. The systolic flow velocity increased by as much as 40%, and the diastolic flow velocity increased by as much as 80%. The flow velocities of the ophthalmic artery and the central retinal artery are frequently decreased in certain ocular diseases, and this decreased flow may contribute to the ocular pathology. If intravenous PGE1 is able to increase the flow velocity of these vessels in patients with peripheral vascular disease, it is possible that it is also able to increase the flow velocity of these vessels in patients with ocular disease as well. Intravenous PGE1 may prove to be a useful adjunct therapy in eyes when ischemia is part of the pathology.
Authors:
R D Steigerwalt; G V Belcaro; V Christopoulos; L Incandela; M R Cesarone; M T De Sanctis
Related Documents :
157116 - Quantitative transcutaneous arterial velocity measurements with doppler flowmeters.
3261886 - The effects of three electrotherapeutic methods on blood velocities in human peripheral...
1498566 - Blood flow velocity waveform in the common carotid artery and its analysis in elderly s...
8600956 - Measurement of blood flow in the superior sagittal sinus in healthy volunteers, and in ...
22556036 - Blood product storage: does age really matter?
11756716 - Mr flow mapping in coronary artery bypass grafts: a validation study with doppler flow ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  17     ISSN:  1080-7683     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2002-01-04     Completed Date:  2002-06-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  529-35     Citation Subset:  IM    
Affiliation:
Angiology and Vascular Surgery Center, San Valentino, Pescara, Italy. r.steigerwalt@libero.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alprostadil / administration & dosage*
Blood Flow Velocity / drug effects,  physiology
Blood Pressure / drug effects
Diabetes Complications
Diabetes Mellitus / physiopathology*
Female
Humans
Injections, Intravenous
Intermittent Claudication / drug therapy,  etiology,  physiopathology
Laser-Doppler Flowmetry
Male
Middle Aged
Ophthalmic Artery / drug effects*
Peripheral Vascular Diseases / complications,  drug therapy,  physiopathology*
Retinal Artery / drug effects*
Vasodilator Agents / administration & dosage*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of topical unoprostone on circulation of human optic nerve head and retina.
Next Document:  Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol an...